Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - CymaBay Therapeutics, Inc. | d313525dex311.htm |
| EX-31.2 - EX-31.2 - CymaBay Therapeutics, Inc. | d313525dex312.htm |
| EX-32.1 - EX-32.1 - CymaBay Therapeutics, Inc. | d313525dex321.htm |
| EX-10.27 - EX-10.27 - CymaBay Therapeutics, Inc. | d313525dex1027.htm |
| EX-10.19 - EX-10.19 - CymaBay Therapeutics, Inc. | d313525dex1019.htm |
| EX-10.28 - EX-10.28 - CymaBay Therapeutics, Inc. | d313525dex1028.htm |
| 10-K - FORM 10-K - CymaBay Therapeutics, Inc. | d313525d10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statements (Form S-3 File Nos. 333-200006 and 333-192617) of CymaBay Therapeutics, Inc., and
(2) Registration Statements (Form S-8 File Nos. 333-195211, 333-198289 and 333-202941) pertaining to the Metabolex, Inc. 2003 Equity Incentive Plan, and the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan,
of our report dated March 23, 2017, with respect to the financial statements of CymaBay Therapeutics, Inc. included in this Annual Report (Form 10-K) of CymaBay Therapeutics, Inc. for the year ended December 31, 2016.
/S/ ERNST & YOUNG LLP
Redwood City, California
March 23, 2017